Cleerly
AI-based analysis for cardiovascular disease risk assessment.
Analyzes coronary CT angiography scans to quantify plaque and arterial conditions. Its AI identifies cardiovascular risks before symptoms appear, allowing for earlier intervention and targeted cardiac care.
PROS
- + Detects high-risk soft (non-calcified) plaque that traditional calcium scoring misses
- + Provides quantitative
- + actionable data on plaque composition
- + stenosis
- + and ischemia likelihood
- + Enables early detection and proactive intervention
- + aiming to prevent heart attacks
- + Reduces the need for downstream unnecessary invasive procedures like coronary angiography
- + FDA-cleared solution built on extensive clinical research and trials
CONS
- - Requires a preceding Coronary CT Angiography (CCTA) scan
- - which involves radiation and contrast agents
- - High initial cost for the analysis
- - though insurance and Medicare coverage is expanding
- - Analysis and reporting require supervision by a physician with advanced CCTA training
-
Quantifying total atherosclerosis plaque burden
-
volume
-
and type from CCTA scans
-
Non-invasively predicting the likelihood of myocardial ischemia (reduced blood flow)
-
Guiding personalized preventive treatment plans and lifestyle modifications for heart disease
-
Tracking changes in plaque buildup over time for longitudinal disease management
-
Screening high-risk
-
asymptomatic patients for early-stage coronary artery disease
SIMILAR TOOLS
Claude Healthcare
Claude helps healthcare organizations move faster without sacrificing accuracy, safety, or compliance. Less administrative work, more time with the people you serve.
ChatGPT Health
A dedicated experience in ChatGPT designed for health and wellness.
Verily
Precision health platform for research and patient care.
Medtronic (AI Surgery & Diabetes)
AI integrated into surgical robotics and chronic disease.